Zerlasiran-A 小型干渉RNAターゲティングリポプロテイン (a): ランダム化2期臨床試験
Steven E Nissen1, Qiuqing Wang1, Stephen J Nicholls2
1Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio.
JAMA
|November 18, 2024
まとめ
血栓硬化性心血管疾患 (ASCVD) の患者では,ゼルラシランがリポプロテイン (a) レベルを80%以上大幅に低下させた. この小さな干渉RNA治療はASCVDの危険因子の管理に有望である.
科学分野:
- 心血管医学
- 薬理学について
- 遺伝学
背景:
- 脂質タンパク質の上昇は,動脈硬化性心血管疾患 (ASCVD) と大動脈狭窄の重要な危険因子です.
- アポリポプロテイン (a) の肝臓合成をターゲットにすることで,リポプロテイン (a) レベルを下げるための潜在的な治療戦略を提供します.
研究 の 目的:
- 小型の干渉RNA (siRNA) の治療薬であるZerlasiranの血清脂質タンパク質 (a) 濃度を下げる効果を評価する.
- 既定のASCVD患者におけるZerlasiranの安全性と耐容性を評価する.
主な方法:
- 安定したASCVDと増加した脂質タンパク質 (a) (≥125 nmol/ L) を含む多センターランダム化試験.
- 参加者は,最大3回の投与で16週間または24週間に一度,皮下プラセボまたは異なる量のZerlasiran (300 mgまたは450 mg) を投与された.
- 主なアウトカムは,ベースラインから36週までのリポプロテイン (a) の時間平均の変化でした.
主要な成果:
- プラセボと比較して,Zerlasiranの治療は,時間平均の変化が - 81. 3%から - 85. 6%の間で,リポプロテイン (a) 濃度の大幅な低下をもたらしました.
- ゼラシラン群では,36週間の中位数減少が顕著で,最大96. 4%に達した.
- 最も一般的な有害事象は注射部位での軽度な反応であり,研究薬に関連する重大な有害事象は認められませんでした.
結論:
- ゼルラシランは,ASCVD患者における脂質タンパク質の濃度を有効かつ有意に低下させる.
- siRNA治療は好ましい安全性プロファイルを示し,高血脂タンパク質と関連した心臓血管リスクの管理のための治療の可能性を示唆しています.
関連する概念動画
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Blinding
2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Bioavailability Study Design: Single Versus Multiple Dose Studies
388
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
388
Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
410
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
410


